Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
182.72
-0.91 (-0.50%)
Mar 6, 2026, 11:17 AM EST - Market open
Jazz Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 4,268 | 4,069 | 3,834 | 3,659 | 3,094 | Upgrade
|
| Revenue Growth (YoY) | 4.88% | 6.12% | 4.78% | 18.26% | 30.91% | Upgrade
|
| Cost of Revenue | 355.35 | 310.7 | 284.13 | 267.13 | 217.68 | Upgrade
|
| Gross Profit | 3,912 | 3,758 | 3,550 | 3,392 | 2,877 | Upgrade
|
| Selling, General & Admin | 1,517 | 1,416 | 1,307 | 1,399 | 1,399 | Upgrade
|
| Research & Development | 751.09 | 851.06 | 818.39 | 555.41 | 476.33 | Upgrade
|
| Amortization of Goodwill & Intangibles | 654.66 | 627.31 | 608.28 | 599.17 | 525.77 | Upgrade
|
| Operating Expenses | 2,923 | 2,894 | 2,734 | 2,553 | 2,401 | Upgrade
|
| Operating Income | 989.07 | 864.14 | 816.23 | 839.14 | 475.26 | Upgrade
|
| Interest Expense | -280.85 | -344.4 | -354.54 | -299.74 | -280.57 | Upgrade
|
| Interest & Investment Income | 85.8 | 106.3 | 65.1 | 11.5 | 1.8 | Upgrade
|
| Earnings From Equity Investments | -0.73 | -1.66 | -3.01 | -9.92 | -0.71 | Upgrade
|
| Currency Exchange Gain (Loss) | -2.57 | -8.18 | 8.79 | -19.01 | -4.35 | Upgrade
|
| EBT Excluding Unusual Items | 790.72 | 616.21 | 532.57 | 521.97 | 191.43 | Upgrade
|
| Merger & Restructuring Charges | -147.95 | -137.51 | -156.95 | -326.88 | -304.99 | Upgrade
|
| Asset Writedown | - | - | -61.7 | -133.65 | - | Upgrade
|
| Legal Settlements | -323.5 | - | - | - | - | Upgrade
|
| Pretax Income | -628.59 | 468.69 | 294.92 | -382.71 | -113.55 | Upgrade
|
| Income Tax Expense | -272.44 | -91.43 | -119.91 | -158.65 | 216.12 | Upgrade
|
| Earnings From Continuing Operations | -356.15 | 560.12 | 414.83 | -224.06 | -329.67 | Upgrade
|
| Net Income | -356.15 | 560.12 | 414.83 | -224.06 | -329.67 | Upgrade
|
| Net Income to Common | -356.15 | 560.12 | 414.83 | -224.06 | -329.67 | Upgrade
|
| Net Income Growth | - | 35.02% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 61 | 62 | 63 | 63 | 60 | Upgrade
|
| Shares Outstanding (Diluted) | 61 | 66 | 72 | 63 | 60 | Upgrade
|
| Shares Change (YoY) | -7.61% | -8.41% | 15.23% | 4.77% | 5.62% | Upgrade
|
| EPS (Basic) | -5.84 | 9.06 | 6.55 | -3.58 | -5.52 | Upgrade
|
| EPS (Diluted) | -5.84 | 8.65 | 6.10 | -3.58 | -5.52 | Upgrade
|
| EPS Growth | - | 41.75% | - | - | - | Upgrade
|
| Free Cash Flow | 1,297 | 1,358 | 1,068 | 1,243 | 750.87 | Upgrade
|
| Free Cash Flow Per Share | 21.27 | 20.57 | 14.82 | 19.87 | 12.58 | Upgrade
|
| Gross Margin | 91.67% | 92.36% | 92.59% | 92.70% | 92.97% | Upgrade
|
| Operating Margin | 23.18% | 21.24% | 21.29% | 22.93% | 15.36% | Upgrade
|
| Profit Margin | -8.34% | 13.77% | 10.82% | -6.12% | -10.65% | Upgrade
|
| Free Cash Flow Margin | 30.39% | 33.37% | 27.86% | 33.97% | 24.27% | Upgrade
|
| EBITDA | 1,685 | 1,524 | 1,455 | 1,469 | 1,028 | Upgrade
|
| EBITDA Margin | 39.49% | 37.46% | 37.95% | 40.13% | 33.22% | Upgrade
|
| D&A For EBITDA | 696.3 | 660.07 | 638.7 | 629.47 | 552.48 | Upgrade
|
| EBIT | 989.07 | 864.14 | 816.23 | 839.14 | 475.26 | Upgrade
|
| EBIT Margin | 23.18% | 21.24% | 21.29% | 22.93% | 15.36% | Upgrade
|
| Revenue as Reported | 4,268 | 4,069 | 3,834 | 3,659 | 3,094 | Upgrade
|
| Advertising Expenses | 105.6 | 107.4 | 92.2 | 108.8 | 161.5 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.